AstraZeneca's Covid vaccine suffers a setback in nasal spray trial
The immune response measured in the blood was weaker than that from a shot-in-the-arm vaccination11-10-2022
11-10-2022
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the attached request for loss of share certificate from the claimant06-10-2022
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the attached request for loss of share certificate from the claimant27-09-2022
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith Certificate dated September 8, 2022 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.19-09-2022
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the attached request for loss of share certificate from the claimant19-09-2022
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Closure of Trading Window
This is to inform you that, in accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the Shares of the Company shall be closed from September 16, 2022 and the same shall reopen after 48 hours from the declaration of Unaudited Financial Results of the Company for the quarter ending September 30, 2022.15-09-2022
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Increase In Volume
This has reference to your email dated September 13, 2022 bearing reference no. L/SURV/ONL/PV/SR/ 2022-2023 / 191 on the captioned subject. We wish to inform you that we have no information/announcement including pending announcement which in the Company's opinion may have a bearing on the price/volume behaviour in the scrip. We thank you for drawing our attention and assure you of Company's continued adherence to its obligation under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.13-09-2022
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Clarification sought from AstraZeneca Pharma India Ltd
The Exchange has sought clarification from AstraZeneca Pharma India Ltd on September 13, 2022, with reference to Movement in Volume.The reply is awaited.13-09-2022
AstraZeneca looks to more than double new cancer drugs by 2030
The UK drugmaker has added seven new cancer medicines since 2014, after Chief Executive Officer Pascal Soriot made a risky bet on an oncology pipeline to revive growth and ward off a hostile takeover from Pfizer Inc.12-09-2022
Tech is now integral part of how we work as a company'
Technologies like extended reality (XR), which includes AR and VR, have huge potential to transform the entire life sciences industry, says Siva Padmanabhan, MD, AstraZeneca India06-09-2022